CORRECTION FROM THE SOURCE: FloraWorks Highlights New Study Showing CBN Reverses Cognitive Decline in Aging Mice
Salk Institute Study Shows FloraWorks CBN Reverses Age-Related Cognitive Decline".Portland, Oregon--(Newsfile Corp. - July 28, 2025) - FloraWorks, a developer of high-purity rare cannabinoid ingredients, is drawing attention to new peer-reviewed research demonstrating that Cannabinol (CBN) can reverse cognitive decline in aging mice. The study, published in the journal Redox Biology, used a high-purity CBN isolate supplied by FloraWorks, produced through...
2025-07-28 12:15 PM EDT
Salk Institute Study Shows FloraWorks' CBN Reverses Age-Related Cognitive Decline
Portland, Oregon--(Newsfile Corp. - July 7, 2025) - In a groundbreaking study published in Redox Biology, researchers at the Salk Institute for Biological Studies have demonstrated that Cannabinol (CBN)-specifically FloraWorks' high-purity TruCBN™-can prevent and/or reverse cognitive decline in a preclinical model of accelerated aging. The findings position CBN as a leading candidate in the development of safe, natural therapeutics for age-related brain and metabolic dysfunction.The study,...
2025-07-07 8:00 AM EDT
FloraWorks Announces Peer-Reviewed Publication of Groundbreaking Sleep Study on TruCBN(TM)
Portland, Oregon--(Newsfile Corp. - July 31, 2024) - FloraWorks, a leader in cannabinoid therapeutic development, is proud to announce the peer-reviewed publication of its groundbreaking study on TruCBN™ in the journal Pharmaceuticals. This landmark research represents the first clinically validated sleep claim for a cannabinoid, underscoring the therapeutic efficacy of TruCBN™ in enhancing sleep quality.TruCBN™ is a proprietary ultra-pure version of Cannabinol (CBN), a cannabinoid that is...
2024-07-31 9:00 AM EDT
FloraWorks Appoints Dr. Matthew Roberts as Chief Operating Officer to Drive Next Phase of Growth
Portland, Oregon--(Newsfile Corp. - July 8, 2024) - FloraWorks, a leading innovator in the development and commercialization of cannabinoid therapeutics, is pleased to announce the appointment of Dr. Matthew Roberts as Chief Operating Officer (COO). With an extensive background in operational leadership, strategic development, and scientific innovation, Dr. Roberts will play a pivotal role in guiding FloraWorks through its next phase of growth and expansion.Dr. Roberts brings over 25 years of...
2024-07-08 8:00 AM EDT
Clinical Validation Data for FloraWorks' TruCBN to be Presented at SLEEP 2024
Portland, Oregon--(Newsfile Corp. - May 30, 2024) - FloraWorks, a lead discovery and validation company advancing research of rare and novel cannabinoids for a new generation of safe and effective therapeutic solutions, announced that an abstract featuring data from a clinical study evaluating TruCBN™ has been accepted as a poster presentation at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies. The poster presentation is scheduled for June 3 from 10:00 AM to...
2024-05-30 11:00 AM EDT
Healthcare Industry Veteran Donald M. Casey Jr. Joins Board of Directors at Cannabinoid Biotech Leader FloraWorks
Portland, Oregon--(Newsfile Corp. - January 4, 2024) - FloraWorks Holdings Inc., a leading cannabinoid biotech company, announced the appointment of Donald M. Casey Jr. as Board Director. Casey brings over 30 years of global healthcare experience to the FloraWorks board, with an outstanding track record of identifying and commercializing medical innovations.Casey has held numerous executive leadership and board tenures, starting with 24 years at Johnson & Johnson where he rose through the...
2024-01-04 9:00 AM EST
Cannabinoid Biotech Leader FloraWorks to Present at Seed Showcase 2024 During J.P. Morgan Healthcare Conference
Portland, Oregon--(Newsfile Corp. - January 4, 2024) - FloraWorks Holdings Inc., a leading cannabinoid therapeutics company, announced it will present at Seed Showcase, part of Biotech Showcase 2024, during this year's annual J.P. Morgan Healthcare Conference in San Francisco, CA. Attendees can view FloraWorks' presentation live during the in-person event on Tuesday, January 9th at 2:20 p.m. PT in the Franciscan-D presentation room.Lindquist will present the Company's groundbreaking approach...
2024-01-04 9:00 AM EST
FloraWorks Appoints Cannabis Scientist Dr. Mike McCormick as VP of Strategy
Portland, Oregon--(Newsfile Corp. - October 4, 2023) - FloraWorks Holdings Inc., a leading cannabinoid therapeutics company, announced the appointment of Dr. Mike McCormick as VP of Strategy. A science and intellectual property consultant for FloraWorks since 2022, Dr. McCormick brings extensive expertise in cannabinoid biochemistry, innovation, and IP protection.Within the cannabis industry, Dr. McCormick focuses on industrial and academic technology transfer, and the development of...
2023-10-04 9:00 AM EDT
FloraWorks Announces Updated Analysis of Landmark Clinical Trial; CBN Shown Effective for Sleep
Portland, Oregon--(Newsfile Corp. - September 18, 2023) - FloraWorks Holdings Inc., a leading cannabinoid therapeutics company, announced that its flagship product TruCBN™ (a pure form of cannabinol or "CBN") demonstrated effectiveness in treating sleep disturbances in a recent landmark clinical trial independently conducted by Radicle Science. In the industry-first, double-blind, randomized, placebo-controlled trial, 25, 50, and 100 milligrams of TruCBN™ were found to significantly enhance...
2023-09-18 9:00 AM EDT
FloraWorks Announces Scientific Breakthrough in Natural Sleep Aids: First-Ever Double-Blind, Randomized, Placebo-Controlled Clinical Trial Discovers CBN Effective for Sleep
Portland, Oregon--(Newsfile Corp. - June 28, 2023) - A landmark study led by FloraWorks Holdings Inc. ("FloraWorks" or "Company"), a leading cannabinoid therapeutics company, announced the results of the first-ever double-blind, randomized, placebo-controlled trial that analyzed the effects of its flagship product, TruCBN™ - a pure form of Cannabinol ("CBN") and one of more than 100 known cannabinoids found in the cannabis plant - on sleep. Independently conducted by clinical-research...
2023-06-28 7:00 AM EDT
FloraWorks Closes $2.25M Series-A with Round Led by Bonaventure Equity
Portland, Oregon--(Newsfile Corp. - June 22, 2023) - FloraWorks Holdings Inc. ("FloraWorks" or "Company"), a leading cannabinoid therapeutics company that specializes in rare and novel cannabinoids, announced the successful completion of a $2.25M Series-A financing round. The round was led by Bonaventure Equity LLC ("BVE"), a life sciences venture capital firm investing in cannabinoid and psychedelic discoveries, with participation from ArcView Group, a global leader serving the cannabis and...
2023-06-22 12:31 PM EDT
FloraWorks Announces the Closing of Lead Investor in Series A Financing
Portland, Oregon--(Newsfile Corp. - December 15, 2022) - FloraWorks Holdings Inc. (the "Company" or "FloraWorks"), a biotech company specializing in rare and novel cannabinoids, is pleased to announce the initial closing of its Series A financing with its lead investor BVE Select Fund II, L.P., the second life sciences venture fund of Bonaventure Equity, LLC ("BVE"). BVE's Founder and Managing Partner, Ross O'Brien, will be joining the Company's board of directors. This latest round of...
2022-12-15 4:30 PM EST
CBN Has Become the Leading Growth Catalyst in the Cannabis Edible Market
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - FloraWorks Holdings Inc. ("FloraWorks" or the "Company") FloraWorks, is closely tracking the growth of CBN adoption within the hemp and cannabis industry. Using data from Headset, a leading cannabis market intelligence service, the company has created the Q1 2021 CBN Market Report to give you a glimpse into the early growth phase of the rapidly emerging market demand for CBN products.Cannabinol or CBN for short, is a rare...
2021-05-04 10:00 AM EDT
Also Known as "The Sleep Cannabinoid", Cannabinol (CBN) Is Now Available in Commercial Quantities
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2020) - FloraWorks Holdings Inc. ("FloraWorks" or the "Company") Cannabinol (CBN), the rare cannabinoid often only found in trace amounts of aged cannabis has been shown to have unique physiological effects that have already started gaining traction for consumer health applications. FloraWorks is excited to announce that after significant research and development efforts, the Company is now manufacturing highly-pure, hemp-derived CBN...
2020-06-09 5:00 AM EDT